Prognostic value of sputum HMGB1 in smear-negative and smear-positive pulmonary TB
The International Journal of Tuberculosis and Lung Disease · 2026
DOI: 10.5588/ijtld.25.0186 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2026. Verfasst von S Kamolratanakul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;, Tropical Immunology and Translational…. Hauptthemen laut MEDLINE: Sputum, HMGB1 Protein, Tuberculosis, Pulmonary.
Abstract (Originalsprache)
BACKGROUND
Diagnosing pulmonary TB (PTB) in patients with negative sputum acid-fast bacillus (AFB) staining is challenging and impedes transmission control. This study assessed the prognostic utility of sputum high-mobility group box protein 1 (HMGB1) in PTB, focusing on treatment outcomes.
METHODS
In a prospective cohort study, we enrolled 66 PTB patients: 37 smear-positive (MTB-MC) and 29 smear-negative but clinically suspected (MTB-SN), confirmed by bacteriology or treatment response. All underwent GeneXpert MTB/RIF testing. Sputum HMGB1 levels were measured at baseline, 2 months, and 6 months post-treatment.
RESULTS
Of the 66 participants, 37 had bacteriologically confirmed PTB (MTB-MC) with AFB grades ranging from scanty (n = 6) to 3+ (n = 12), and 29 had smear-negative PTB (MTB-SN). Sputum HMGB1 levels declined significantly during treatment ( P < 0.001). Baseline HMGB1 strongly correlated with bacillary load ( r 2 = 0.4645, P < 0.0001). Notably, 2-month HMGB1 levels predicted culture conversion, with an area under the curve of 0.885 for treatment failure in the MTB-MC group.
CONCLUSION
Sputum HMGB1 is a promising marker for monitoring treatment response and predicting failure in PTB, especially in smear-negative cases. Despite limited diagnostic specificity due to elevation in inflammatory conditions, its role in assessing 2-month culture conversion warrants further study. Larger studies are needed to validate clinical thresholds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;, Tropical Immunology and Translational Research Unit (TITRU), Department of Clinical Tropical Medicine, Facu…
- Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;, Center of Excellence on Translational Research in Inflammation and Immunology (CETRII), Department of Microbiology, Faculty…
- Department of Medicine, Banphaeo General Hospital, Samut Sakhon, Thailand.
- Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Zitieren
APA
Kamolratanakul, S., Bhunyakarnjanarat, T., Ariyanon, W., Wilairatana, P., Leelahavanichkul, A., & Chancharoenthana, W. (2026). Prognostic value of sputum HMGB1 in smear-negative and smear-positive pulmonary TB. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.25.0186
Vancouver
Kamolratanakul S, Bhunyakarnjanarat T, Ariyanon W, Wilairatana P, Leelahavanichkul A, Chancharoenthana W. Prognostic value of sputum HMGB1 in smear-negative and smear-positive pulmonary TB. The International Journal of Tuberculosis and Lung Disease. 2026. doi:10.5588/ijtld.25.0186
BibTeX
@article{Kamolratanakul2026,
author = {Kamolratanakul, S and Bhunyakarnjanarat, T and Ariyanon, W and Wilairatana, P and Leelahavanichkul, A and Chancharoenthana, W},
title = {Prognostic value of sputum HMGB1 in smear-negative and smear-positive pulmonary TB},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2026},
doi = {10.5588/ijtld.25.0186}
}
EUVIMED